Silencing NEDD4L Effectively Inhibits the Malignant Behaviors of Hepatocellular Carcinoma

Junze Dai,1,2,* Tong Zhu,3,* Jun Wan,4,* Ruibin Liu,5 Yuxuan Song,5 Dingye Zhang,5 Xin Wang,5 Huiyu Zhang,5 Wenxin Li,2,* Jie Lin,5 Xudong Zhu,5,6 Yefu Liu2,6 1Graduate School, Dalian Medical University, Dalian, Liaoning, 116044, People’s Republic of C...

Full description

Saved in:
Bibliographic Details
Main Authors: Dai J, Zhu T, Wan J, Liu R, Song Y, Zhang D, Wang X, Zhang H, Li W, Lin J, Zhu X, Liu Y
Format: Article
Language:English
Published: Dove Medical Press 2025-07-01
Series:Journal of Hepatocellular Carcinoma
Subjects:
Online Access:https://www.dovepress.com/silencing-nedd4l-effectively-inhibits-the-malignant-behaviors-of-hepat-peer-reviewed-fulltext-article-JHC
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850117427202883584
author Dai J
Zhu T
Wan J
Liu R
Song Y
Zhang D
Wang X
Zhang H
Li W
Lin J
Zhu X
Liu Y
author_facet Dai J
Zhu T
Wan J
Liu R
Song Y
Zhang D
Wang X
Zhang H
Li W
Lin J
Zhu X
Liu Y
author_sort Dai J
collection DOAJ
description Junze Dai,1,2,* Tong Zhu,3,* Jun Wan,4,* Ruibin Liu,5 Yuxuan Song,5 Dingye Zhang,5 Xin Wang,5 Huiyu Zhang,5 Wenxin Li,2,* Jie Lin,5 Xudong Zhu,5,6 Yefu Liu2,6 1Graduate School, Dalian Medical University, Dalian, Liaoning, 116044, People’s Republic of China; 2Department of Hepatopancreatobiliary Surgery, Cancer Hospital of China Medical University, Liaoning Cancer Hospital & Institute, Shenyang, Liaoning, 110042, People’s Republic of China; 3Department of Breast Surgery, Panjin Central Hospital, Panjin, 124010, People’s Republic of China; 4Second General Surgery Department, Central Hospital of Shenyang Sujiatun, Shenyang, Liaoning, 110101, People’s Republic of China; 5Department of General Surgery, Cancer Hospital of Dalian University of Technology, Cancer Hospital of China Medical University, Liaoning Cancer Hospital & Institute, Shenyang, Liaoning, 110042, People’s Republic of China; 6Liaoning Provincial Key Laboratory of Precision Medicine for Malignant Tumors, Shenyang, Liaoning, 110042, People’s Republic of China*These authors contributed equally to this workCorrespondence: Xudong Zhu, Department of General Surgery, Cancer Hospital of Dalian University of Technology, Cancer Hospital of China Medical University, Liaoning Cancer Hospital & Institute, Shenyang, Liaoning, 110042, People’s Republic of China, Email xdzhu@cmu.edu.cn Yefu Liu, Department of Hepatopancreatobiliary Surgery, Cancer Hospital of China Medical University, Liaoning Cancer Hospital & Institute, No. 44 Xiaoheyan Road, Dadong District, Shenyang, Liaoning, 110042, People’s Republic of China, Email 97902153@cmu.edu.cnBackground: NEDD4L, an E3 ubiquitin ligase, has served a pivotal function in the malignant progression of different cancers. However, research focusing on its involvement in hepatocellular carcinoma (HCC) remains relatively scarce.Methods: This investigation examined NEDD4L’s expression, survival implications, and regulatory mechanisms of NEDD4L in HCC using RNA-seq and microarray data across multiple databases. Additionally, we investigated the impact of NEDD4L expression on malignant biological behaviors of HCC by in vitro functional assays including Edu, CCK-8, Transwell, and wound healing assay. Finally, single-cell sequencing data from HCC patients were employed to further investigate and validate NEDD4L expression patterns across various stages of HCC and its immune functional states.Results: NEDD4L was identified as one of the most markedly differentially expressed genes linked to ubiquitination in HCC and was noted to be an independent prognostic marker for overall survival, with higher expression levels correlating with poorer outcomes. Knockdown of NEDD4L significantly inhibited cell proliferation, migration, and scratch healing ability in HCC. Moreover, NEDD4L expression was closely linked to the regulation of the cell cycle and DNA damage repair, potentially driving abnormal cell cycle progression and HCC development by mediating the degradation of inhibitory cell cycle checkpoints or their upstream transcription factors via ubiquitination. Single-cell sequencing analysis revealed that NEDD4L was notably enriched in cancer stem cell populations across different HCC developmental stages and immune states, with subgroups exhibiting high NEDD4L expression sharing substantial co-expressed genes with stem cell subpopulations. Furthermore, an analysis of NEDD4L’s relationships with immune infiltration indicated that NEDD4L could facilitate immune evasion in HCC by downregulating stimulatory immune checkpoints and immune cell infiltration, a phenomenon also observed in other types of tumors.Conclusion: These findings indicate that NEDD4L is upregulated in HCC and strongly associated with unfavorable patient outcomes, pointing to its prospective utility as a biomarker for HCC. Furthermore, silencing NEDD4L could effectively inhibit the malignant behaviors of HCC. Given its dual role in regulating both cell cycle and immune checkpoints, NEDD4L represents a promising therapeutic target for HCC. Targeting NEDD4L could potentially enhance the efficacy of cyclin-dependent kinase inhibitors and immune checkpoint inhibitors.Keywords: hepatocellular carcinoma, immune suppression, NEDD4L, therapeutic target
format Article
id doaj-art-808d4fba98f6447c8d154d0e48fb629c
institution OA Journals
issn 2253-5969
language English
publishDate 2025-07-01
publisher Dove Medical Press
record_format Article
series Journal of Hepatocellular Carcinoma
spelling doaj-art-808d4fba98f6447c8d154d0e48fb629c2025-08-20T02:36:06ZengDove Medical PressJournal of Hepatocellular Carcinoma2253-59692025-07-01Volume 12Issue 113691391104670Silencing NEDD4L Effectively Inhibits the Malignant Behaviors of Hepatocellular CarcinomaDai J0Zhu T1Wan J2Liu RSong YZhang DWang XZhang HLi WLin J3Zhu X4Liu Y5Dalian Medical UniversityDepartment of Breast SurgeryDepartment of General SurgeryDepartment of General SurgeryDepartment of General SurgeryDepartment of Hepatobiliary and Pancreatic SurgeryJunze Dai,1,2,* Tong Zhu,3,* Jun Wan,4,* Ruibin Liu,5 Yuxuan Song,5 Dingye Zhang,5 Xin Wang,5 Huiyu Zhang,5 Wenxin Li,2,* Jie Lin,5 Xudong Zhu,5,6 Yefu Liu2,6 1Graduate School, Dalian Medical University, Dalian, Liaoning, 116044, People’s Republic of China; 2Department of Hepatopancreatobiliary Surgery, Cancer Hospital of China Medical University, Liaoning Cancer Hospital & Institute, Shenyang, Liaoning, 110042, People’s Republic of China; 3Department of Breast Surgery, Panjin Central Hospital, Panjin, 124010, People’s Republic of China; 4Second General Surgery Department, Central Hospital of Shenyang Sujiatun, Shenyang, Liaoning, 110101, People’s Republic of China; 5Department of General Surgery, Cancer Hospital of Dalian University of Technology, Cancer Hospital of China Medical University, Liaoning Cancer Hospital & Institute, Shenyang, Liaoning, 110042, People’s Republic of China; 6Liaoning Provincial Key Laboratory of Precision Medicine for Malignant Tumors, Shenyang, Liaoning, 110042, People’s Republic of China*These authors contributed equally to this workCorrespondence: Xudong Zhu, Department of General Surgery, Cancer Hospital of Dalian University of Technology, Cancer Hospital of China Medical University, Liaoning Cancer Hospital & Institute, Shenyang, Liaoning, 110042, People’s Republic of China, Email xdzhu@cmu.edu.cn Yefu Liu, Department of Hepatopancreatobiliary Surgery, Cancer Hospital of China Medical University, Liaoning Cancer Hospital & Institute, No. 44 Xiaoheyan Road, Dadong District, Shenyang, Liaoning, 110042, People’s Republic of China, Email 97902153@cmu.edu.cnBackground: NEDD4L, an E3 ubiquitin ligase, has served a pivotal function in the malignant progression of different cancers. However, research focusing on its involvement in hepatocellular carcinoma (HCC) remains relatively scarce.Methods: This investigation examined NEDD4L’s expression, survival implications, and regulatory mechanisms of NEDD4L in HCC using RNA-seq and microarray data across multiple databases. Additionally, we investigated the impact of NEDD4L expression on malignant biological behaviors of HCC by in vitro functional assays including Edu, CCK-8, Transwell, and wound healing assay. Finally, single-cell sequencing data from HCC patients were employed to further investigate and validate NEDD4L expression patterns across various stages of HCC and its immune functional states.Results: NEDD4L was identified as one of the most markedly differentially expressed genes linked to ubiquitination in HCC and was noted to be an independent prognostic marker for overall survival, with higher expression levels correlating with poorer outcomes. Knockdown of NEDD4L significantly inhibited cell proliferation, migration, and scratch healing ability in HCC. Moreover, NEDD4L expression was closely linked to the regulation of the cell cycle and DNA damage repair, potentially driving abnormal cell cycle progression and HCC development by mediating the degradation of inhibitory cell cycle checkpoints or their upstream transcription factors via ubiquitination. Single-cell sequencing analysis revealed that NEDD4L was notably enriched in cancer stem cell populations across different HCC developmental stages and immune states, with subgroups exhibiting high NEDD4L expression sharing substantial co-expressed genes with stem cell subpopulations. Furthermore, an analysis of NEDD4L’s relationships with immune infiltration indicated that NEDD4L could facilitate immune evasion in HCC by downregulating stimulatory immune checkpoints and immune cell infiltration, a phenomenon also observed in other types of tumors.Conclusion: These findings indicate that NEDD4L is upregulated in HCC and strongly associated with unfavorable patient outcomes, pointing to its prospective utility as a biomarker for HCC. Furthermore, silencing NEDD4L could effectively inhibit the malignant behaviors of HCC. Given its dual role in regulating both cell cycle and immune checkpoints, NEDD4L represents a promising therapeutic target for HCC. Targeting NEDD4L could potentially enhance the efficacy of cyclin-dependent kinase inhibitors and immune checkpoint inhibitors.Keywords: hepatocellular carcinoma, immune suppression, NEDD4L, therapeutic targethttps://www.dovepress.com/silencing-nedd4l-effectively-inhibits-the-malignant-behaviors-of-hepat-peer-reviewed-fulltext-article-JHCHepatocellular carcinomaImmune suppressionNEDD4LTherapeutic target
spellingShingle Dai J
Zhu T
Wan J
Liu R
Song Y
Zhang D
Wang X
Zhang H
Li W
Lin J
Zhu X
Liu Y
Silencing NEDD4L Effectively Inhibits the Malignant Behaviors of Hepatocellular Carcinoma
Journal of Hepatocellular Carcinoma
Hepatocellular carcinoma
Immune suppression
NEDD4L
Therapeutic target
title Silencing NEDD4L Effectively Inhibits the Malignant Behaviors of Hepatocellular Carcinoma
title_full Silencing NEDD4L Effectively Inhibits the Malignant Behaviors of Hepatocellular Carcinoma
title_fullStr Silencing NEDD4L Effectively Inhibits the Malignant Behaviors of Hepatocellular Carcinoma
title_full_unstemmed Silencing NEDD4L Effectively Inhibits the Malignant Behaviors of Hepatocellular Carcinoma
title_short Silencing NEDD4L Effectively Inhibits the Malignant Behaviors of Hepatocellular Carcinoma
title_sort silencing nedd4l effectively inhibits the malignant behaviors of hepatocellular carcinoma
topic Hepatocellular carcinoma
Immune suppression
NEDD4L
Therapeutic target
url https://www.dovepress.com/silencing-nedd4l-effectively-inhibits-the-malignant-behaviors-of-hepat-peer-reviewed-fulltext-article-JHC
work_keys_str_mv AT daij silencingnedd4leffectivelyinhibitsthemalignantbehaviorsofhepatocellularcarcinoma
AT zhut silencingnedd4leffectivelyinhibitsthemalignantbehaviorsofhepatocellularcarcinoma
AT wanj silencingnedd4leffectivelyinhibitsthemalignantbehaviorsofhepatocellularcarcinoma
AT liur silencingnedd4leffectivelyinhibitsthemalignantbehaviorsofhepatocellularcarcinoma
AT songy silencingnedd4leffectivelyinhibitsthemalignantbehaviorsofhepatocellularcarcinoma
AT zhangd silencingnedd4leffectivelyinhibitsthemalignantbehaviorsofhepatocellularcarcinoma
AT wangx silencingnedd4leffectivelyinhibitsthemalignantbehaviorsofhepatocellularcarcinoma
AT zhangh silencingnedd4leffectivelyinhibitsthemalignantbehaviorsofhepatocellularcarcinoma
AT liw silencingnedd4leffectivelyinhibitsthemalignantbehaviorsofhepatocellularcarcinoma
AT linj silencingnedd4leffectivelyinhibitsthemalignantbehaviorsofhepatocellularcarcinoma
AT zhux silencingnedd4leffectivelyinhibitsthemalignantbehaviorsofhepatocellularcarcinoma
AT liuy silencingnedd4leffectivelyinhibitsthemalignantbehaviorsofhepatocellularcarcinoma